Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Humylub Ofteno PF** is an ophthalmic solution containing **sodium hyaluronate 0.1%** and **chondroitin sulfate 0.18%**, developed by **Laboratorios Sophia** for the treatment of mild to moderate **dry eye disease**. It functions as a lubricant by mimicking natural tears, with sodium hyaluronate providing viscoelastic hydration to the ocular surface and chondroitin sulfate enhancing mucoadhesion and protection against epithelial damage. The product is preservative-free (PF), suitable for frequent use, and has demonstrated efficacy in improving symptoms (OSDI score), tear break-up time, ocular staining, and hyperemia in a completed Phase 4 non-inferiority trial against comparators like Hyabak and Lagricel Ofteno PF.[1][3][8][10]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Humylub Ofteno PF.